Chunghwa Chemical Synthesis & Biotech Co (TPE:1762) Beneish M-Score: -17.95 (As of Jul. 12, 2026)


TPE:1762 Chunghwa Chemical Synthesis & Biotech Co Ltd TPE:1762
58 GF Score
Price NT$38.15
GF Value NT$37.92
Valuation Fairly Valued
! 8 Warning Signs
View Full Analysis

What is Chunghwa Chemical Synthesis & Biotech Co Beneish M-Score?

Chunghwa Chemical Synthesis & Biotech Co TPE:1762 58 Beneish M-Score is -17.95 as of Jul. 12, 2026. GuruFocus rates TPE:1762 with a GF Score™ of 58/100 and a GF Value™ of NT$37.92 (Fairly Valued). The stock has 8 warning signs investors should review. Among 825 Biotechnology companies, Chunghwa Chemical Synthesis & Biotech Co ranks better than 99.27% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -17.95 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Chunghwa Chemical Synthesis & Biotech Co's Beneish M-Score or its related term are showing as below:

TPE:1762' s Beneish M-Score Range Over the Past 10 Years
Min: -17.95   Med: -2.45   Max: -0.84
Current: -17.95

During the past 13 years, the highest Beneish M-Score of Chunghwa Chemical Synthesis & Biotech Co was -0.84. The lowest was -17.95. And the median was -2.45.


Chunghwa Chemical Synthesis & Biotech Co Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Chunghwa Chemical Synthesis & Biotech Co's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Chunghwa Chemical Synthesis & Biotech Co Beneish M-Score Chart

Chunghwa Chemical Synthesis & Biotech Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.45 -2.89 -2.32 -2.82 -17.95

Chunghwa Chemical Synthesis & Biotech Co Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.82 -3.57 -2.30 -2.98 -17.95

TPE:1762 vs VRTX, REGN, ALNY: Beneish M-Score Comparison

For the Biotechnology subindustry, Chunghwa Chemical Synthesis & Biotech Co's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Chunghwa Chemical Synthesis & Biotech Co Beneish M-Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Chunghwa Chemical Synthesis & Biotech Co's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Chunghwa Chemical Synthesis & Biotech Co's Beneish M-Score falls into.


TPE:1762
58GF Score
Chunghwa Chemical Synthesis & Biotech Co Ltd TPE:1762
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Chunghwa Chemical Synthesis & Biotech Co Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Chunghwa Chemical Synthesis & Biotech Co for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.8115+0.528 * -26.5737+0.404 * 1.1778+0.892 * 0.5974+0.115 * 0.9771
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.3081+4.679 * -0.089513-0.327 * 0.9373
=-17.95

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec25) TTM:Last Year (Dec24) TTM:
Total Receivables was NT$96.6 Mil.
Revenue was 113.417 + 154.47 + 344.039 + 192.952 = NT$804.9 Mil.
Gross Profit was -89.392 + -9.223 + 29.22 + 60.531 = NT$-8.9 Mil.
Total Current Assets was NT$1,058.9 Mil.
Total Assets was NT$4,317.4 Mil.
Property, Plant and Equipment(Net PPE) was NT$2,060.6 Mil.
Depreciation, Depletion and Amortization(DDA) was NT$191.3 Mil.
Selling, General, & Admin. Expense(SGA) was NT$142.3 Mil.
Total Current Liabilities was NT$356.7 Mil.
Long-Term Debt & Capital Lease Obligation was NT$602.8 Mil.
Net Income was -141.254 + -42.579 + -67.332 + 7.318 = NT$-243.8 Mil.
Non Operating Income was 0 + 0 + 0 + 0 = NT$0.0 Mil.
Cash Flow from Operations was -20.593 + 112.625 + -25.564 + 76.143 = NT$142.6 Mil.
Total Receivables was NT$199.3 Mil.
Revenue was 286.325 + 348.18 + 461.158 + 251.712 = NT$1,347.4 Mil.
Gross Profit was 71.443 + 87.878 + 117.701 + 117.296 = NT$394.3 Mil.
Total Current Assets was NT$1,441.2 Mil.
Total Assets was NT$4,762.7 Mil.
Property, Plant and Equipment(Net PPE) was NT$2,199.5 Mil.
Depreciation, Depletion and Amortization(DDA) was NT$199.2 Mil.
Selling, General, & Admin. Expense(SGA) was NT$182.1 Mil.
Total Current Liabilities was NT$425.3 Mil.
Long-Term Debt & Capital Lease Obligation was NT$704.0 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(96.611 / 804.878) / (199.303 / 1347.375)
=0.120032 / 0.147919
=0.8115

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(394.318 / 1347.375) / (-8.864 / 804.878)
=0.292656 / -0.011013
=-26.5737

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (1058.883 + 2060.561) / 4317.353) / (1 - (1441.225 + 2199.467) / 4762.738)
=0.277464 / 0.235588
=1.1778

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=804.878 / 1347.375
=0.5974

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(199.156 / (199.156 + 2199.467)) / (191.348 / (191.348 + 2060.561))
=0.083029 / 0.084971
=0.9771

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(142.326 / 804.878) / (182.135 / 1347.375)
=0.176829 / 0.135178
=1.3081

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((602.789 + 356.706) / 4317.353) / ((703.979 + 425.288) / 4762.738)
=0.222241 / 0.237105
=0.9373

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-243.847 - 0 - 142.611) / 4317.353
=-0.089513

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Chunghwa Chemical Synthesis & Biotech Co has a M-score of -17.95 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -17.95 mean?
Chunghwa Chemical Synthesis & Biotech Co (TPE:1762) has a Beneish M-Score of -17.95 as of Jul. 12, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Chunghwa Chemical Synthesis & Biotech Co and its competitors. According to the industry distribution chart, Chunghwa Chemical Synthesis & Biotech Co ranks #6 out of 825 companies in the Biotechnology industry, placing it in the top 0.7%.
Is Chunghwa Chemical Synthesis & Biotech Co's Beneish M-Score too high?
Chunghwa Chemical Synthesis & Biotech Co's current Beneish M-Score is -17.95. Based on the distribution chart, Chunghwa Chemical Synthesis & Biotech Co ranks #6 out of 825 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Chunghwa Chemical Synthesis & Biotech Co has a GF Score™ of 58/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Chunghwa Chemical Synthesis & Biotech Co's Beneish M-Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Chunghwa Chemical Synthesis & Biotech Co ranks #6 out of 825 companies for Beneish M-Score. This places Chunghwa Chemical Synthesis & Biotech Co in the top 1% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Biotechnology company?
A good Beneish M-Score depends on the Biotechnology industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Chunghwa Chemical Synthesis & Biotech Co and its competitors. Chunghwa Chemical Synthesis & Biotech Co's current Beneish M-Score is -17.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chunghwa Chemical Synthesis & Biotech Co stock overvalued right now?
Based on GuruFocus' analysis, Chunghwa Chemical Synthesis & Biotech Co (TPE:1762) is currently considered Fairly Valued. The stock's GF Value™ is NT$37.92, compared to a current price of NT$38.15 — trading 0.6% above its estimated fair value. The current Beneish M-Score is -17.95. Chunghwa Chemical Synthesis & Biotech Co's overall GF Score™ is 58/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Chunghwa Chemical Synthesis & Biotech Co (TPE:1762), the current Beneish M-Score is -17.95 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Chunghwa Chemical Synthesis & Biotech Co (TPE:1762) Overvalued in 2026?

Based on GuruFocus' analysis, Chunghwa Chemical Synthesis & Biotech Co stock appears to be overvalued. The current stock price of NT$38.15 is trading 0.6% above its estimated GF Value™ of NT$37.92. GuruFocus considers Chunghwa Chemical Synthesis & Biotech Co to be Fairly Valued.

Key valuation signals for TPE:1762:

  • Beneish M-Score: -17.95
  • GF Value™: NT$37.92 vs. price of NT$38.15 (0.6% above fair value)
  • GF Score™: 58/100 with 8 warning signs

No single metric tells the full story. See the TPE:1762 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Chunghwa Chemical Synthesis & Biotech Co Business Description

Address No. 1, Dongxing Street, Shulin District, Taipei, TWN
Chunghwa Chemical Synthesis & Biotech Co Ltd is engaged in the research, development, manufacturing, and sales of pharmaceutical products. Geographically, it derives a majority of its revenue from the United States and also has a presence in Taiwan. Its product portfolio comprises pain management, antifungal, immunosuppressant, oncology, Cardiovascular, Peptide Drugs, and Others.
58GF Score

Get the complete analysis for TPE:1762

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$38.15
Price
NT$37.92
GF Value